Caffeine as a psychomotor stimulant: Mechanism of action

Cellular and Molecular Life Sciences

Volumn 61, Issue 7-8, 2004, Pages 857-872

  Fisone, G ^a   Borgkvist, A ^a   Usiello, A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adenosine; Adenosine A2A receptors; Basal ganglia; Dopamine; Dopamine and cAMP regulated phosphoprotein of 32 kDa; Immediate early gene; Motor activity; Parkinson's disease

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; AMPHETAMINE; CAFFEINE; COCAINE; CYCLIC AMP; DOPAMINE; METHYLXANTHINE; PHOSPHOPROTEIN DARPP 32; PSYCHOTROPIC AGENT;

4 AMINOBUTYRIC ACID BRAIN LEVEL; BASAL GANGLION; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; GENE EXPRESSION; IMMEDIATE EARLY GENE; INTRACELLULAR MEMBRANE; MOTOR CONTROL; NEUROPROTECTION; PARKINSON DISEASE; PSYCHOMOTOR ACTIVITY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BASAL GANGLIA; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; ENZYME INHIBITORS; HUMANS; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHOSPHOPROTEINS; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 2442696513     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-003-3269-3     Document Type: Review

References (190)

1. Butcher R. W. and Sutherland E. W. (1962) Adenosine 3′,5′- monophosphate in biological materials. I. Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5′-phosphate in human urine. J. Biol. Chem. 237: 1244-1250
2. Vernikos-Danellis J. and Harris III C. G. (1968) The effect of in vitro and in vivo caffeine, theophylline and hydrocortisone on the phosphodiesterase activity of the pituitary, median eminence, heart and cerebral cortex. Proc. Soc. Exp. Biol. Med. 128: 1016-1021
3. Cardinali D. P. (1980) Methylxanthines: possible mechanisms of action in the brain. Trends Pharmacol. Sci. 1: 405-407
4. McPherson P. S., Kim Y. K., Valdivia H., Knudson C. M., Takekura H., Franzini-Armstrong C. et al. (1991) The brain ryanodine receptor: a caffeine-sensitive calcium release channel. Neuron 7: 17-25
5. 2+ release. Trends Pharmacol. Sci. 16: 386-391
6. Marangos P. J., Paul S. M., Parma A. M., Goodwin F. K., Syapin P. and Skolnick P. (1979) Purinergic inhibition of diazepam binding to rat brain (in vitro). Life Sci. 24: 851-858
7. Davies L. P., Chow S. C. and Johnson G. A. R. (1984) Interaction of purines and related compounds with photoaffinity-labelled benzodiazepine binding sites. Eur. J. Pharmacol. 97: 325-329
8. A receptors. Cell. Mol. Neurobiol. 23: 331-347
9. Daly J. W. (2000) Alkylxanthines as research tools. J. Auton. Nerv. Syst. 81: 44-52
10. Dews P. B. (1982) Caffeine. Annu. Rev. Nutr. 2: 323-341
11. Bonati M., Latini R., Galletti F., Young J. F., Tognoni G. and Garattini S. (1982) Caffeine disposition after oral doses. Clin. Pharmacol. Ther. 32: 98-106
12. Fredholm B. B., Bättig K., Holmén J., Nehlig A. and Zvvartau E. E. (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51: 83-133
13. Dunwiddie T. V. and Masino S. A. (2001) The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 24: 31-55
14. Zimmerman H. and Braun N. (1999) Ecto-nucleotidases - molecular structures, catalytic properties and functional roles in the nervous system. Prog. Brain Res. 120: 371-385
15. Schubert P., Komp W. and Kreutzberg G. W. (1979) Correlation of 5′-nucleotidase activity and selective transneuronal transfer of adenosine in the hippocampus. Brain Res. 168: 419-424
16. Broch O. J. and Ueland P. M. (1980) Regional and subcellular distribution of S-adenosylhomocysteine hydrolase in the adult rat brain. J. Neurochem. 35: 484-488
17. Dunwiddie T. V. and Diao L. H. (1994) Extracellular adenosine in hippocampal brain slices and the tonic inhibitory modulation of evoked excitatory responses. J. Pharmacol. Exp. Ther. 268: 537-545
18. Ballarin M., Fredholm B. B., Ambrosio S. and Mahy N. (1991) Extracellular levels of adenosine and its metabolites in the striatum of awake rats: inhibition of uptake. Acta Physiol. Scand. 142: 97-103
19. Lloyd H. G. and Fredholm B.B. (1995) Involvement of adenosine deaminase and adenosine kinase in regulating extracellular adenosine concentration in hippocampal slices. J. Neurochem. 26: 387-395
20. Arch J. R. and Newsholme E. A. (1978) The control of the metabolism and the hormonal role of adenosine. Essays Biochem. 14: 82-123
21. Cass C. E., Young J. D. and Baldwin S. A. (1998) Recent advances in the molecular biology of nucleoside transporters of mammalian cells. Biochem. Cell Biol. 76: 761-770
22. Williams T. C. and Jarvis S. M. (1991) Multiple sodium-dependent nucleoside transport systems in bovine renal brush-border membrane vesicles. Biochem. J. 274: 27-33
23. Anderson C. M., Xiong W., Young J. D., Cass C. E. and Parkinson F. E. (1996) Demonstration of the existence of mRNA encoding N1/cif and N2/cit sodium/nucleoside cotransporters in the brain. Brain Res. Mol. Brain Res. 42: 358-361
24. Berne R. M., Rubio R. and Curnish R. R. (1974) Release of adenosine from ischemic brain. Effect on cerebral vascular resistance and incorporation into cerebral adenine nucleotide. Circ. Res. 35: 262-271
25. Zetterström T., Vernet L., Ungerstedt U., Tossman U. and Jonzon B. (1982) Purine levels in the intact brain. Studies with an implanted perfused hollow fibre. Neurosci. Lett. 29: 111-115
26. Pull I. and McIlwain H. (1972) Adenine derivatives as neurohumoral agents in the brain. The quantities liberated on excitation of superfused cerebral tissues. Biochem. J. 130: 975-981
27. Lloyd H. G., Linström K. and Fredholm B. B. (1993) Intracellular formation and release of adenosine from rat hippocampal slices evoked by electrical stimulation or energy depletion. Neurochem. Int. 23: 173-185
28. Fredholm B. B., Abbracchio M. P., Burnstock G., Daly J. W., Harden T. K., Jacobson K. A. et al. (1994) Nomenclatuure and classification of purinoceptors. Pharmacol. Rev. 46: 143-156
29. 3 receptors: novel ligands and paradoxical effects. Trends Pharmacol. Sci. 19: 184-191
30. 2B receptors. Pharmacol. Rev. 49: 381-402
31. Londos C., Cooper D. M. F. and Wolff J. (1980) Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci. USA 77: 2551-2554
32. van Calker D., Mueller M. and Hamprecht B. (1979) Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 33: 999-1005
33. Trussel L. O. and Jackson M. B. (1985) Adenosine-activated potassium conductance in cultured striatal neurons. Proc. Natl. Acad. Sci. USA 82: 4857-4861
34. Macdonald R. L., Skerrit J. H. and Werz M. A. (1986) Adenosine agonists reduce voltage-dependent calcium conductance of mouse sensory neurones in cell culture. J. Physiol. 370: 75-90
35. olf levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J. Neurosci. 21: 4390-4399
36. 3H]cyclohexyladenosine. J. Neurosci. 2: 1230-1241
37. 1-adenosine receptor that is widely expressed in brain and spinal cord. Mol. Endocrinol. 5: 1037-1048
38. 1 adenosine receptor from rat brain. Mol. Pharmacol. 40: 1-7
39. Rivkees S. A., Price S. L. and Zhou F. C. (1995) Immunohistochemical detection of A1 adenosine receptors in rat brain with emphasis on localization in the hippocampal formation, cerebral cortex, cerebellum and basal ganglia. Brain Res. 677: 193-203
40. Fredholm B. B. and Dunwiddie T. V. (1988) How does adenosine inhibit transmitter release? Trends Pharmacol. Sci. 9: 130-134
41. 2A receptor activation on the evoked release of glutamate from cerebrocortical synaptosomes. Br. J. Pharmacol. 136: 434-440
42. Flagmeyer I., Haas H. L. and Stevens D. R. (1997) Adenosine A1 receptor-mediated depression of corticostriatal and thalamostriatal glutamatergic synaptic potentials in vitro. Brain Res. 778: 178-185
43. Dunwiddie T. V. and Hoffer B. J. (1980) Adenine nucleotides and synaptic transmission in the in vitro rat hippocampus. Br. J. Pharmacol. 69: 59-68
44. Okada M., Mizuno K. and Kaneko S. (1996) Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci. Lett. 212: 53-56
45. Brown S. J., James S., Reddington M. and Richardson P. J. (1990) Both A1 and A2a purine receptors regulate striatal acetylcholine release. J. Neurochem. 55: 31-38
46. Rainnie D. G., Grunze H. C., McCarley R. W. and Greene R. W. (1994) Adenosine inhibition of mesopontine cholinergic neurons: implications for EEG arousal. Science 263: 689-692
47. Arushanian E. B. and Belozertsev Y. B. (1978) The effect of amphetamine and caffeine on neuronal activity in the neocortex of the cat. Neuropharmacology 17: 1-6
48. Phillis J. W. and Kostopoulos G. K. (1975) Adenosine as a putative transmitter in the cerebral cortex: studies with potentiators and antagonists. Life Sci. 17: 1085-1094
49. Dunwiddie T. V., Hoffer B. J. and Fredholm B. B. (1981) Alkylxanthines elevate hippocampal excitability: evidence for a role of endogenous adenosine. Naunyn-Schmiedeberg's Arch. Pharmacol. 316: 326-330
50. Popoli P., Sagratella S. and Scotti de Carolis A. (1987) An EEG and behavioural study on the excitatory properties of caffeine in rabbits. Arch. Int. Pharmacodyn. Ther. 290: 5-15
51. Acquas E., Tanda G. and Di Chiara G. (2002) Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine pretreated rats. Neuropsychopharmacology 27: 182-193
52. Himmelheber A. M., Sarter M. and Bruno J. P. (2000) Increases in cortical acetylcholine release during sustained attention performance in rats. Cogn. Brain Res. 9: 313-325
53. Passetti F., Dalley J. W., O'Connell M. T., Everitt B. J. and Robbins T. W. (2000) Increased acetylcholine release in the rat medial prefrontal cortex during performance of a visual attentional task. Eur. J. Neurosci. 12: 3051-3058
54. 3H]CGS 21680. Eur. J. Pharmacol. 168: 243-246
55. 3H]-CGS 21680 as a ligand. Naunyn-Schmiedeberg's Arch. Pharmac. 342: 85-89
56. 3H]CGS 21680 to human and rat brain: evidence for multiple affinity sites. J. Neurochem. 55: 1763-1771
57. 2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience 42: 697-706
58. Schiffman S. N., Jacobs O. and Vanderhaegen J. J. (1991) Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57: 1062-1067
59. Fink J. S., Weaver D. R., Rivkees S. A., Peterfreund R. A., Pollack A. E., Adler E. M. et al. (1992) Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptor in rat striatum. Mol. Brain Res. 14: 186-195
60. Schiffman S. N. and Vanderhaeghen J.-J. (1993) Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. 13: 1080-1087
61. Alexander G. E., DeLong M. R. and Strick P. L. (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9: 357-381
62. Ungerstedt U. (1971) Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand. 367: 1-48
63. Dahlström A. and Fuxe K. (1964) Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in cell bodies of brain stem neurons. Acta Physiol. Scand. 62: 1-55
64. Andén N.-E., Carlsson A., Dahlström A., Fuxe K., Hillarp N.-Å. and Larsson K. (1964) Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci. 3: 523-530
65. Gerfen C. R. (1992) The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Ann. Rev. Neurosci. 15: 285-320
66. Stoof J. C. and Kebabian J. W. (1981) Opposing roles for D-1 and D-2 dopamine rceptors in efflux of cyclic AMP from rat neostriatum. Nature 294: 366-368
67. 1 receptor signaling. J. Neurosci. 20: RC91 (1-5)
68. 2 receptors in rat neostriatal membranes. Eur. J. Pharmacol. 244: 311-315
69. 2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. USA 88: 7238-7241
70. Ferré S., Fredholm B. B., Morelli M., Popoli P. and Fuxe K. (1997) Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20: 482-487
71. Fredholm B. B. (1977) Activation of adenylate cyclase from rat striatum and tuberculum olfactorium by adenosine. Med. Biol. 55: 262-267
72. 2 receptor knockout mice. Proc. Natl. Acad. Sci. USA 98: 1970-1975
73. 2 receptor interaction in globus pallidus. Synapse 22: 132-138
74. Ferré S., O'Connor W. T., Fuxe K. and Ungerstedt U. (1993) The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci. 13: 5402-5406
75. Aoyama S., Kase H. and Borrelli (2000) Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J. Neurosci. 20: 5848-5852
76. 2 receptors. J. Neurosci. 20: 5949-5957
77. Nehlig A., Daval J. L. and Debry G. (1992) Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res. Rev. 17: 139-170
78. Daly J. W. and Fredholm B. B. (1998) Caffeine - an atypical drug of dependence. Drug Alcohol Dep. 51: 199-206
79. Waldeck B. (1975) Effect of caffeine on locomotor activity and central catecholamine mechanisms: a study with special reference to drug interaction. Acta Pharmacol. Toxicol. 36 (Suppl. IV): 1-23
80. Snyder S. H., Katims J. J., Annau A., Bruns R. F. and Daly J. W. (1981) Adenosine receptors in the central nervous system: relationship to the central actions of methylxanthines. Life Sci. 28: 2083-2097
81. Fredholm B. B. (1980) Are methyllxanthine effects due to antagonism of endogenous adenosine? Trends Pharmacol. Sci. 1: 129-132
82. Davis J. M., Zhao Z., Stock H. S., Mehl K. A., Buggy J. and Hand G. A. (2003) Central nervous system effects of caffeine and adenosine on fatigue. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284: R399-R404
83. 2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience 79: 753-764
84. Garrett B. and Holtzman S. G. (1993) D1 and D2 dopamine receptor antagonists block caffeine-induced stimulation of locomotor activity in rats. Pharmacol. Biochem. Behav. 47: 89-94
85. Finn I. B. and Holtzman S. G. (1986) Tolerance to caffeine-induced stimulation of locomotor activity in rats. J. Pharmacol. Exp. Ther. 238: 542-546
86. Svenningsson P., Nomikos G. G. and Fredholm B. B. (1995) Biphasic changes in locomotor behavior and in expresssion of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration. J. Neurosci. 15: 7612-7624
87. Nikodijeviç O. and Jacobson K. A. (1993) Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacol. Biochem. Behav. 44: 199-216
88. Logan L., Seale T. W. and Carney J. M. (1986) Inherent differences in sensitivity to methylxanthines among inbred mice. Pharmacol. Biochem. Behav. 24: 1281-1286
89. 2A receptors. Br. J. Pharmacol. 129: 1465-1473
90. 2-selective adenosine agonists: evidence for synergism and antagonism. J. Pharmacol. Exp. Ther. 259: 286-294
91. Katims J. J., Annau Z. and Snyder S. H. (1983) Interactions in the behavioral effects of methylxanthines and adenosine derivatives. J. Pharmacol. Exp. Ther. 227: 167-173
92. Okada M., Kiryu K., Kawata Y., Mizuno K., Wada K., Tasaki H. et al. (1997) Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis. Eur. J. Pharmacol. 321: 181-188
93. Morgan M. E. and Vestal R. E. (1989) Methylxanthine effects on caudate dopamine release as measured by in vivo electrochemistry. Life Sci. 45: 2025-2039
94. Solinas M., Ferré S., You Z.-B., Karcz-Kubicha M., Popoli P. and Goldberg S. R. (2002) Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J. Neurosci. 22: 6321-6324
95. Swerdlow N. R. and Koob G. F. (1985) Separate neural substrates of the locomotor-activating properties of amphetamine, heroin, caffeine and corticotropin releasing factor (CRF) in the rat. Pharmacol. Biochem. Behav. 23: 303-307
96. Pulvirenti L., Swerdlow N. R. and Koob G. F. (1991) Nucleus accumbens NMDA antagonist decreases locomotor activity produced by cocaine, heroin or accumbens dopamine, but not caffeine. Pharmacol. Biochem. Behav. 40: 841-845
97. Joyce E. M. and Koob G. F. (1981) Amphetamine-, scopolamine- and caffeine-induced locomotor activity following 6-hydroxydopamine lesions of the mesolimbic dopamine system. Psychopharmacology (Berl.) 73: 311-313
98. 2A adenosine receptor antagonist. J. Pharmacol. Exp. Ther. 276: 398-404
99. 1-selective adenosine antagonist 8-cyclopentyl-l,3-dipropylxanthine to rat brain membranes. Naunyn-Schmiedeberg's Arch. Pharmac. 335: 59-63
100. Griebel G., Misslin R. and Vogel E. (1991) Behavioural effects of selective A2 adenosine receptor antagonists, CGS 21197 and CGS 22706, in mice. Neuroreport 2: 139-140
101. Griebel G., Saffroy-Spittler M., Misslin R., Remmy D., Vogel E. and Bourguignon J.-J. (1991) Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 15943A and an A1-selective antagonist, DPCPX. Psychopharmacology (Berl.) 103: 541-544
102. Lindskog M., Svenningsson P., Pozzi L., Kim Y., Fienberg A. A., Bibb J. A. et al. (2002) Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature 418: 774-778
103. Ledent C., Vaugeois J. M., Schiffman S. N., Pedrazzini T., El Yacoubi M., Vanderhaegen J. J. et al. (1997) Aggressiveness, hypoalgesia and increased blood pressure in mice deficient for the adenosine A2a receptor. Nature 388: 674-678
104. Ferré S., Herrera-Marschitz M., Grabowska-Andén M., Casas M., Ungerstedt U. and Andén N-E. (1991) Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. Eur. J. Pharmacol. 192: 31-37
105. White B. C., Simpson C. C., Adams J. E. and Harkins D. J. (1978) Monoamine synthesis and caffeine-induced locomotor activity. Neuropharmacology 17: 511-513
106. 2 receptor agonists but not to their synergistic interaction. Eur. J. Pharmacol. 262: 65-75
107. Braun R. L., Barone P. and Chase T. N. (1986) Interaction of D1 and D2 dopamine receptors in the expression of dopamine agonist-induced behavior. Adv. Med. Biol. 204: 151-166
108. Popoli P., Caporali M. G. and Scotti de Carolis A. (1991) Akinesia due to catecholamine depletion in mice is prevented by caffeine. Further evidence for an involvement of adenosinergic system in the control of motility. J. Pharm. Pharmacol. 43: 280-281
109. Shiozaki S., Ichikawa S., Nakamura J., Kitamura S., Yamada K. and Kuwana Y. (1999) Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl.) 147: 90-95
110. Kanda T., Jackson M. J., Smith L. A., Pearce R. K., Nakamura J., Kase H. et al. (1998) Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43: 507-513
111. Dragunow M. and Faull R. (1989) The use of c-fos as a metabolic marker in neuronal pathways tracing. J. Neurosci. Methods 29: 261-265
112. Hughes P. and Dragunow M. (1995) Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol. Rev. 47: 133-178
113. Miller J. C. (1990) Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. J. Neurochem. 54: 1453-1455
114. Robertson G. S. and Fibiger H. C. (1992) Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46: 315-328
115. Dragunow M., Robertson G. S., Faull R. L. M., Robertson H. A. and Jansen K. (1990) D2 dopamine receptor antagonists induce c-fos and related proteins in rat striatal neurons. Neuroscience 37: 287-294
116. Young S. T., Porrino L. J. and Iadarola M. J. (1991) Cocaine induces striatal c-fos-immunoreactive proteins via dopaminergic D1 receptors. Proc. Natl. Acad. Sci. USA 88: 1291-1295
117. Graybiel A. M., Moratalla R. and Robertson H. A. (1990) Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc. Natl. Acad. Sci. USA 87: 6912-6916
118. Svenningsson P., Ström A., Johansson B. and Fredholm B. B. (1995) Increased expression of c-jun, junB, AP-1 and preproenkephalin mRNA in rat striatum following a single injection of caffeine. J. Neurosci. 15: 3583-3593
119. 1 receptors in the striatum: different interactions with the dopaminergic system. Eur. J. Neurosci. 11: 3101-3114
120. Nakajima T., Daval J. L., Morgan P. F., Post R. M. and Marangos P. J. (1989) Adenosinergic modulation of caffeine-induced c-fos mRNA expression in mouse brain. Brain Res. 501: 307-314
121. Gonzales G. A. and Montminy M. R. (1989) Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59: 675-680
122. Sheng M. and Greenberg M. E. (1990) The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron 4: 477-485
123. Cole D. G. and DiFiglia M. (1994) Reserpine increases fos activity in the rat basal ganglia via a quinpirole-sensitive mechanism. Neuroscience 60: 115-123
124. 2 dopamne-dependent activation of Fos in the striatopallidal pathway. Neuroscience 68: 721-728
125. Boegman R. J. and Vincent S. R. (1996) Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse 22: 70-77
126. Ouimet C. C., Langley-Guillion K.-C. and Greengard P. (1998) Quantitative immunochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res. 808: 8-12
127. Greengard P., Allen P. B. and Nairn A. (1999) Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23: 435-447
128. Fienberg A. A., Hiroi N., Mermelsten P., Song W.-J., Snyder G. L., Nishi A. et al. (1998) DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281: 838-842
129. Hemmings J., H.C., Greengard P., Tung H. Y. L. and Cohen P. (1984) DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310: 503-505
130. Bibb J., Snyder G. L., Nishi A., Yan Z., Meijer L., Fienberg A. A. et al. (1999) Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402: 669-671
131. Nishi A., Bibb J. A., Snyder G. L., Higashi H., Nairn A. C. and Greengard P. (2000) Amplification of dopaminergic signaling by a positive feedback loop. Proc. Natl. Acad. Sci. USA 97: 12840-12845
132. Usui H., Imazu M., Maeta K., Tsukamoto H., Azuma K. and Takeda M. (1988) Three distinct forms of type 2A protein phosphatase in human erythrocyte cytosol. J. Biol. Chem. 263: 3752-3761
133. Usui H., Inoue R., Tanabe O., Nishito Y., Shimizu M., Hayashi H. et al. (1998) Activation of protein phosphatase 2A by cAMP-dependent protein kinase-catalyzed phosphorylation of the 74-kDa B″ (delta) regulatory subunit in vitro and identification of the phosphorylation sites. FEBS Lett. 430: 312-316
134. Nishi A., Snyder G. L. and Greengard P. (1997) Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17: 8147-8155
135. 1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience 84: 223-228
136. Surmeier D. J., Bargas J., Hemmings H. C., Nairn A. C. and Greengard P. (1995) Modulation of calcium currents by a D1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons. Neuron 14: 385-397
137. Snyder G. L., Fienberg A. A., Huganir R. L. and Greengard P. (1998) A dopamine/D1 receptor/protein kinase A/dopamine-and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J. Neurosci. 18: 10297-10303
138. Snyder G. L., Allen P. B., Fienberg A. A., Valle C. G., Huganir R. L., Nairn A. C. et al. (2000) Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo. J. Neurosci. 20: 4480-4488
139. A receptor currents in neostriatal neurons through a PKA/DARPP-32/PP-1 signaling cascade. J. Neurophysiol. 83: 2996-3004
140. Bibb J. A., Chen J., Taylor J. R., Svenningsson P., Nishi A., Snyder G. L. et al. (2001) Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature 410: 376-380
141. 2A receptors. Proc. Natl. Acad. Sci. USA 97: 1856-1860
142. 2A receptors. Prog. Neurobiol. 59: 355-396
143. Grafe M. R., Forno L. S. and Eng L. F. (1985) Immunocytochemical studies of substance P and met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's disease. J. Neuropathol. Exp. Neurol. 44: 47-59
144. Nisbet A. P., Foster O. J., Kingsbury A., Eve D. J., Daniel S. E., Marsden C. D. et al. (1995) Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 66: 361-376
145. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250: 1429-1432
146. Augood S. J., Emson P. C., Mitchell I. J., Boyce S., Clarke C. E. and Crossman A. R. (1989) Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys. Mol. Brain Res. 6: 85-92
147. Ungerstedt U. and Arbuthnott G. W. (1970) Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24: 485-493
148. Ungerstedt U. (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. 367: 69-93
149. Casas M., Ferré S., Cobos A., Grau J. N. and Jané F. (1989) Relationship between rotational behaviour induced by apomorphine and caffeine in rats with unilateral lesions of the nigrostriatal pathway. Neuropsychopharmacology 28: 407-409
150. Fredholm B. B., Herrera-Marschitz M., Jonzon B., Lindström K. and Ungerstedt U. (1983) On the mechanism by which methylxanthines enhance apomorphine-induced rotation behaviour in the rat. Pharmac. Biochem. Behav. 19: 535-541
151. Fuxe K. and Ungerstedt U. (1974) Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med. Biol. 52: 48-54
152. Garrett B. E. and Holtzman S. G. (1995) Does adenosine receptor blockade mediate caffeine-induced rotational behavior? J. Pharmacol. Exp. Ther. 274: 207-214
153. Herrera-Marschitz M., Casas M. and Ungerstedt U. (1988) Caffeine produces contralateral rotation in rats with unilateral dopamine denervation: comparisons with apomorphine-induced responses. Psychopharmacology (Berl.) 94: 38-45
154. Jiang H., Jackson-Lewis V., Muthane U., Dollison A., Ferreira M., Espinosa A. et al. (1993) Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Res. 613: 347-351
155. Wooten G. F. (2001) Anatomy and function of dopamine receptors: understanding the pathophysiology of fluctuations in Parkinson's disease. Park. Rel. Dis. 8: 79-83
156. Pinna A., Fenu S. and Morelli M. (2001) Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39: 233-238
157. 2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 321: 143-147
158. Koga K., Kurokawa M., Ochi M., Nakamura J. and Kuwana Y. (2000) Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur. J. Pharmacol. 408: 249-255
159. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Neurosci. 18: 338-344
160. Grondin R., Bedard P. J., Hadj Tahar A., Gregoire L., Mori A. and Kase H. (1999) Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52: 1673-1677
161. Kanda T., Jackson M. J., Smith L. A., Pearce R. K., Nakamura J., Kase H. et al. (2000) Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. 162: 321-327
162. Kim D. S. and Palmiter R. D. (2003) Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient mice. Proc. Natl. Acad. Sci. USA 100: 1346-1351
163. 2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse 46: 251-257
164. 2A adenosine receptors. J. Neurosci. 22: 1054-1062
165. 2a receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia. J. Neurochem. 84: 1398-1410
166. Winkler C., Kirik D., Björklund A. and Cenci A. M. (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10: 165-186
167. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N. and Cenci A. M. (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15: 120-132
168. Cenci A. M., Whishaw I. Q. and Schauert T. (2002) Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neuroscience 3: 574-579
169. Kartzinel R., Shoulson I. and Calne D. B. (1976) Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism. Neurology 26: 741-743
170. Shoulson I. and Chase T. N. (1975) Caffeine and the antiparkinsonian response to levodopa or piribedil. Neurology 25: 722-724
171. Mally J. and Stone T. W. (1994) The effect of theophylline on parkinsonian symptoms. J. Pharm. Pharmacol. 46: 515-517
172. 2A adenosine receptor antagonists. Psychopharmacology (Berl.) 148: 153-163
173. Ross G. W., Abbott R. D., Petrovich H., Morens D. M., Grandinetti A., Tung K.-H. et al. (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283: 2674-2679
174. Ascherio A., Zhang S. M., Hernán M. A., Kawachi I., Colditz G. A., Speizer F. E. et al. (2001) Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 50: 56-63
175. Chen J.-F., Xu K., Petzer J. P., Staal R., Xu Y.-H., Beilstein M. A. et al. (2001) Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21: RC143 (1-6)
176. 2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 80: 262-270
177. Bona E., Ådén U., Gilland E., Fredholm B. B. and Hagberg H. (1997) Neonatal cerebral hypoxia-ischemia: the effect of adenosine receptor antagonists. Neuropharmacology 36: 1327-1338
178. 2A receptor antagonist. Brain Res. 800: 328-335
179. Monopoli A., Lozza G., Forlani A., Mattavelli A. and Ongini E. (1998) Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 9: 3955-3959
180. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19: 9192-9200
181. Rodriguez M. C., Obeso J. A. and Olanow C. W. (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. 44: S175-S188
182. Bedingfield J. B., King D. A. and Holloway F. A. (1998) Cocaine and caffeine: conditioned place preference, locomotor activity and additivity. Pharmacol. Biochem. Behav. 61: 291-296
183. Misra A. L., Vadlamani N. L. and Pontani R. B. (1986) Effect of caffeine on cocaine locomotor stimulant activity in rats. Pharmacol. Biochem. Behav. 24: 761-764
184. Brockwell N. T., Eikelboom R. and Benninger R. J. (1991) Caffeine- induced place and taste conditioning: production of dose-dependent preference and aversion. Pharmacol. Biochem. Behav. 38: 513-517
185. Holtzman S. G., Mante S. and Minneman K. P. (1991) Role of adenosine receptors in caffeine tolerance. J. Pharmacol. Exp. Ther. 256: 62-68
186. Nehlig A. (1999) Are we dependent upon coffee and caffeine? A review on human and animal data. Neurosci. Biobehav. Rev. 23: 563-576
187. American Psychiatric Association (APA) (1992) Diagnostic and Statististical Manual of Mental Disorders, 4th edn, American Psychiatric Association, Washington, DC
188. Evans S. M. and Griffiths R. R. (1999) Caffeine withdrawal: a parametric analysis of caffeine dosing conditions. J. Pharmacol. Exp. Ther. 289: 285-294
189. Svenningsson P., Nomikos G. G. and Fredholm B. B. (1999) The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions. J. Neurosci. 19: 4011-4022
190. Halldner L., Lozza G., Lindstrom K. and Fredholm B. B. (2000) Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist. Eur. J. Pharmacol. 406: 345-354